go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Gilead Sciences Ltd

Gilead Sciences Ltd
Flowers Building, Granta Park, Abington, Cambridge, Cambridgeshire, CB21 6GT, UK
Telephone: +44 (0)1223 897 300
Fax: +44 (0)1223 897 291
Medical Information Direct Line: +44 (0)1223 897 555
Medical Information e-mail: ukmedinfo@gilead.com
Customer Care direct line: +44 (0)1223 897 400
Medical Information Facsimile: +44 (0)1223 897 281
Summary of Product Characteristics last updated on medicines.ie: 17/08/2011
SPC AmBisome (Liposomal Amphotericin)

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 17/08/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   01-Jul-2011
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company

The amendment to the SPC is as follows:

Section 6.5 –  Inclusion of a 20 ml sterile, Type I glass vial presentation

Date changed for the revision of the text (Section 10)

Updated on 17/05/2011 and displayed until 17/08/2011
Reasons for adding or updating:
  • Change to section 6.3 - Shelf life
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   01-May-2011
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company


  • Clarifying the dosing and reconstitution information in sections 6.3 (shelf life) and 6.6 (special precautions for disposal and other handling)
  • In section 10: Date of the revision of the text- changed to May 2011
Updated on 09/11/2010 and displayed until 17/05/2011
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   01-Oct-2010
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company

Section 1

-Wording changed to AmBisome liposomal amphotericin B 50mg powder for concentrate for dispersion for infusion.

Section 4.2

- Addition of hepatic impairment statement which states no data are available on which to make a dose recommendation for patients with hepatic impairment.

- Removal of the statement in this section that AmBisome is not physically compatible with saline solutions and should not be mixed with other drugs or electrolytes.

Section 4.8

- Addition of the following under musculoskeletal and connective tissue disorders:- Not Known: rhabdomyolysis (associated with hypokalemia).

- Addition of a paragragh on the interference with Phosphorus Chemistry Assays.

Section 6.6

- Addition of statement that AmBisome is NOT interchangeable with other amphotericin products.

- Addition of statement- AmBisome must be reconstituted using Sterile Water for Injection (without a bacteriostatic agent) and diluted in Dextrose solution (5%, 10% or 20%) for infusion only.

- Addition of a section preparation of AmBisome for infusion. This also shows an example of the preparation of AmBisome at a dose of 3 mg/kg/day in dextrose 5%.

Section 10

- Date of the revision of the text changed to October 2010.

Updated on 11/08/2009 and displayed until 09/11/2010
Reasons for adding or updating:
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   01-Mar-2008
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company

In section 10, the date of the revision of the text has been amended to March 2008
Updated on 28/10/2008 and displayed until 11/08/2009
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   08/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Section 1
 
- Name amended to AmBisome 50 mg lyophilisate for solution for infusion.

Section 2

The following statement added:
 
- After reconstitution, the concentrate contains 4 mg/mL amphotericin B.
 
Section 3
 
- Rewording of dosage form.

Section 4.2

- Information added regarding the recommended duration of intravenous infusion in doses greater than 5mg/kg/day.
- Inclusion of adult patients subheading and B following amphotericin.
- Statement that AmBisome is not recommended for use in children below 1 month.
- Statement alteration in elderly patients section.

Section 4.3

- Amendment to contraindication statement.

Section 4.4

- Changes to this section with additional information included with regards special warnings and precautions.

Section 4.5

- Changes to this section with additional information included with regards to interaction.

Section 4.7

- Statement alteration on the effects of AmBisome on the ability to drive/or use machines.

Section 4.8

- Changes with additional information on undesirable effects.
- Amendment to the frequency definitions.
- Addition of not known incidences in the disorders section.

Section 4.9

- Inclusion of the word acute to overdose.

Section 5.1

- Addition of a subheading and B after amphotericin.

Section 5.3

- Statement amendments to doses in dogs, rabbits and rats and non-mutagenic in bacterial and mammalian systems.

Section 6.1

- Excipients listed.

Section 6.2

- Statement alteration with regards incompatibility and mixing with other drugs and electrolytes.

Section 6.3

- Minor amendments with shelf life information.

Section 6.4

- Statement Keep container in outer carton added.
- Statement of Referral to section 6.3 for storage conditions.

Section 6.5

- Statement on the marketing of pack sizes.

Section 6.6

- Addition of yellow dispersion after reconstitution with water for injections statement.
- Includes statements on unused product and waste disposal.

Section 10

- Date changed for the revision of the text.

Updated on 01/05/2008 and displayed until 28/10/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
Date of revision of text on the SPC:   03/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Type II update to section 4.4.
Updated on 29/06/2007 and displayed until 01/05/2008
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 7 - Marketing authorisation holder
Date of revision of text on the SPC:   04/2007
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

All sections of SmPC updated in line with company core safety information.
Updated on 14/03/2007 and displayed until 29/06/2007
Reasons for adding or updating:
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
  • Change to improve clarity and readability
Date of revision of text on the SPC:   12/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

General updates in line with current SmPC requirements. 
 
Further clarification of Sections 1, 2, 3, 6.1, 6.3, 6.4, 6.5 and 6.6. 
 
Section 1 update in line with standard terms.
 
Section 6.4 - removal of requirement to protect AmBisome from light.
 
Section 9 - Date of renewal
 
Section 10 - Date of revision of the text.
Updated on 01/09/2003 and displayed until 14/03/2007
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 25/06/2003 and displayed until 01/09/2003
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Amphotericin B

Versions

 
17/08/2011 to Current
17/05/2011 to 17/08/2011
09/11/2010 to 17/05/2011
11/08/2009 to 09/11/2010
28/10/2008 to 11/08/2009
01/05/2008 to 28/10/2008
29/06/2007 to 01/05/2008
14/03/2007 to 29/06/2007
01/09/2003 to 14/03/2007
25/06/2003 to 01/09/2003
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo